SEC Form 4 · accession 0001209191-17-046026
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 8:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 19, 2017 | M | 6,303 | $96.87 | A | 128,814 | D | |
| Common Stock | Jul 19, 2017 | M | 32,343 | $109.14 | A | 161,157 | D | |
| Common Stock | Jul 19, 2017 | S | 39,833 | $161.00 | D | 121,324 | D | |
| Common StockF2,F3 | Jul 21, 2017 | S | 700 | $158.08 | D | 120,624 | D | |
| Common StockF3,F4 | Jul 21, 2017 | S | 1,000 | $158.92 | D | 119,624 | D | |
| Common StockF3,F5 | Jul 21, 2017 | S | 400 | $159.85 | D | 119,224 | D | |
| Common StockF3,F6 | Jul 21, 2017 | S | 3,464 | $161.38 | D | 115,760 | D | |
| Common StockF3,F7 | Jul 21, 2017 | S | 1,336 | $162.04 | D | 114,424 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F8 | $96.87 | Jul 19, 2017 | M | 6,303 | D | — | Jul 14, 2024 | Common Stock | 6,303 | 6,875 | D |
| Stock Option (Right to Buy)F9 | $109.14 | Jul 19, 2017 | M | 32,343 | D | — | Feb 2, 2025 | Common Stock | 32,343 | 25,157 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $158.08 (range $157.48 to $158.41).
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $158.92 (range $158.61 to $159.48).
- F5Open market sales reported on this line occurred at a weighted average price of $159.85 (range $159.64 to $160.25).
- F6Open market sales reported on this line occurred at a weighted average price of $161.38 (range $160.90 to $161.89).
- F7Open market sales reported on this line occurred at a weighted average price of $162.04 (range $161.90 to $162.38).
- F8The option vests in 16 quarterly installments from 7/15/2014.
- F9The option vests in 16 quarterly installments from 2/3/2015.